TY  - GEN
AU  - Macek Jilkova,Zuzana
AU  - Aspord,Caroline
AU  - Kurma,Keerthi
AU  - Granon,Anouck
AU  - Sengel,Christian
AU  - Sturm,Nathalie
AU  - Marche,Patrice N
AU  - Decaens,Thomas
TI  - Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
SN  - 2155-384X
PY  - 2020///0831
KW  - Aged
KW  - Antigens, CD
KW  - drug effects
KW  - CD4-Positive T-Lymphocytes
KW  - CD8-Positive T-Lymphocytes
KW  - Carcinoma, Hepatocellular
KW  - drug therapy
KW  - Disease Progression
KW  - Female
KW  - Hepatitis A Virus Cellular Receptor 2
KW  - Humans
KW  - Immunotherapy
KW  - methods
KW  - Liver Neoplasms
KW  - pathology
KW  - Male
KW  - Neoplasm Staging
KW  - Predictive Value of Tests
KW  - Prognosis
KW  - Programmed Cell Death 1 Receptor
KW  - antagonists & inhibitors
KW  - Protein Kinase Inhibitors
KW  - therapeutic use
KW  - Sorafenib
KW  - Up-Regulation
KW  - Lymphocyte Activation Gene 3 Protein
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.14309/ctg.0000000000000058
ER  -